BCRX
BioCryst Pharmaceuticals Inc
NASDAQ: BCRX · HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC
$8.99
+1.47% today
Updated 2026-04-29
Market cap
$2.28B
P/E ratio
7.43
P/S ratio
2.61x
EPS (TTM)
$1.21
Dividend yield
—
52W range
$6 – $11
Volume
5.5M
WallStSmart proprietary scores
57
out of 100
Grade: C+
Hold
Investment rating
8.0
Growth
A4.8
Quality
C8.0
Profitability
A5.7
Valuation
C+5/9
Piotroski F-Score
Moderate
-0.3
Altman Z-Score
Distress
—
Industry rank
—
View all highly rated stocks (75+) →201 stocks currently score above 75
Price targets
Analyst target
$21.40
+138.04%
12-Month target
$9.40
+4.56%
Intrinsic (DCF)
—
Margin of safety
—
3 Strong Buy7 Buy0 Hold0 Sell0 Strong Sell
Price chart
X-Ray snapshot
Strengths
+ Profit margin 30.20% — above average
+ Free cash flow $275.23M — positive
+ Revenue growth 209.10% QoQ
Risks
- Altman Z -0.30 — distress zone
Key financials
Revenue Net Income Free Cash Flow
| Metric | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|
| Revenue | $270.83M | $331.41M | $450.71M | $874.84M | $874.84M |
| Net income | $-247.12M | $-226.54M | $-88.88M | $263.86M | $245.84M |
| EPS | — | — | — | — | $1.21 |
| Free cash flow | $-163.20M | $-97.31M | $-53.14M | $327.41M | $275.23M |
| Profit margin | -91.24% | -68.36% | -19.72% | 30.16% | 30.20% |
Peer comparison
Smart narrative
BioCryst Pharmaceuticals Inc trades at $8.99. representing a P/E of 7.43x trailing earnings. Our Smart Value Score of 57/100 indicates the stock is fair. The company scores 5/9 on the Piotroski F-Score. With an Altman Z-Score of -0.30, it sits in the distress. TTM revenue stands at $874.84M. with profit margins at 30.20%.
Frequently asked questions
What is BioCryst Pharmaceuticals Inc's stock price?
BioCryst Pharmaceuticals Inc (BCRX) trades at $8.99.
Is BioCryst Pharmaceuticals Inc overvalued?
Smart Value Score 57/100 (Grade C+, Hold).
What is the price target of BioCryst Pharmaceuticals Inc (BCRX)?
The analyst target price is $21.40, representing +138.0% upside from the current price of $8.99.
What is BioCryst Pharmaceuticals Inc's revenue?
TTM revenue is $874.84M.
Piotroski F-Score?
5/9 — moderate financial health.
Altman Z-Score?
-0.30 — distress.
Company info
SectorHEALTHCARE
IndustryDRUG MANUFACTURERS - SPECIALTY & GENERIC
CountryUSA
ExchangeNASDAQ
CurrencyUSD
Quick metrics
P/S ratio2.61x
ROE-1,925.00%
Beta0.69
50D MA$8.93
200D MA$7.87
Shares out0.25B
Float0.22B
Short ratio—
Avg volume5.5M
Performance
1 week—
1 month—
3 months—
YTD—
1 year—
3 years—
5 years—